Categories Analysis, Consumer, Trending Stocks

Here are two attractive dividend stocks that you should not miss

Both General Mills and Coca-Cola have increased their dividends regularly over the past several years and maintained high yields

Investors usually focus more on income stocks in times of uncertainty and the trend was evident during the coronavirus pandemic. Take a look at these high-yield dividend stocks that have the potential to create long-term value.

The Dividend King

General Mills (NYSE: GIS) is a top-performing Wall Street stock that has a dividend yield of 3.3%, which is among the best in the industry. The grocery retailer has raised its dividend consistently in recent years. The company that owns popular brands like Pillsbury and Cheerios — operating for nearly a century — is an all-time favorite of investors. Though the stock has bounced back from the recent lows, after entering the year on a low note, it remains affordable.


General Mills Inc. Q3 2021 Earnings Call Transcript


If the valuation moderates further, it could have a positive effect on the yield. The strong fundamentals and resilient business model, combined with decent pay-outs, make it a good bet. The pay-out ratio is likely to grow in the coming months if the company’s impressive dividend history is any indication. Last month, General Mills paid $0.51 per share, which was raised from $0.49 last year. 

General Mills Q3 2021 earnings infographic

The company’s financial performance has been stable during the crisis period, despite the widespread disruption. In the third quarter, all the key operating divisions registered growth, riding the elevated demand for food-at-home during the crisis as people continued to avoid eating out. Earnings grew 30% to $0.96 per share, on revenues of $4.5 billion.

The stock is currently trading close to the levels seen twelve months ago, after experiencing volatility during that period. It has gained about 3% since last year and analysts expect the uptrend would continue for the remainder of the year.

Tempting Fizz

The Coco-Cola Company (NYSE: KO) has been a much sought-after stock among income investors. The soft drink behemoth has an impressive track record of dividend hike and offers a yield of about 3%, which is more than double that of the average yield of S&P 500. Interestingly, the company has paid dividends regularly for more than a century. Besides, KO’s resilience to the recent shift in people’s consumption habits and macroeconomic headwinds, including the COVID crisis, underscores the strength of its balance sheet.

The company has grown far beyond the popular Coke brand and the portfolio currently includes a diverse mix of products ranging from tea and coffee to juices and plant-based beverages. It is almost certain that the company would continue raising its dividend in the foreseeable future.

Coca-Cola’s earnings and revenues either beat or matched the estimates over the past several years and it was no different in the most recent quarter. Benefitting from the vaccine-driven market reopening, sales grew 5% to $9 billion in the first quarter, driving up adjusted earnings by 8% to $0.55 per share.  The bottom-line also exceeded analysts’ forecast as demand almost returned to the pre-crisis levels.


Read management/analysts’ comments on Coca-Cola’s Q1 earnings


After slipping to a three-month low in January, Coca-Cola’s stock has recovered steadily and is currently hovering close to last year’s record high. At $52.29, the stock closed the last trading session slightly lower.

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top